Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein

Cancer Research

Volumn 59, Issue 13, 1999, Pages 3134-3142

  Butterfield, Lisa H ^a   Koh, Andrew ^a   Meng, Wilson ^a   Vollmer, Charles M ^a   Ribas, Antoni ^a   Dissette, Vivian ^a   Lee, Eric ^a   Glaspy, John A ^a   McBride, William H ^a   Economou, James S ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; PEPTIDE;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HLA SYSTEM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0033168417     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Ahlgren, J. D., Wanebo, H. J., and Hill, M. C. Hepatocellular carcinoma. In: J. D. Ahlgren and J. S. Macdonald (eds.), Gastrointestinal Oncology, pp. 417-434. Philadelphia: J. B. Lippincott, 1992.
2. Colombo, M. Hepatocellular carcinoma [published erratum appears in J. Hepatol. 1992 Sep;16(1-2):255]. J. Hepatol., 15: 225-236, 1992.
3. Falkson, G., Cnaan, A., Schutt, A. J., Ryan, L. M., and Falkson, H. C. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res., 48: 7314-7318, 1988.
4. Nerenstone, S. R., Ihde, D. C., and Friedman, M. A. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat. Rev., 15: 1-31, 1988.
5. Levin, B., and Amos, C. Therapy of unresectable hepatocellular carcinoma [published erratum appears in N. Engl. J. Med. 1995 Sep 7; 333(10):675]. N. Engl. J. Med., 332: 1294-1296, 1995.
6. Liu, C. L., and Fan, S. T. Nonresectional therapies for hepatocellular carcinoma. Am. J. Surg., 173: 358-365, 1997.
7. Schuster, M. J., and Wu, G. Y. Gene therapy for hepatocellular carcinoma: progress but many stones yet unturned! Gastroenterology, 112: 656-659, 1997.
8. Huber, B. E., Richards, C. A., and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 88: 8039-8043, 1991.
9. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H., and Nagataki, S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res., 55: 3105-3109, 1995.
10. Su, H., Chang, J. C., Xu, S. M., and Kan, Y. W. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Ther., 7: 463-470, 1996.
11. Wills, K. N., Huang, W. M., Harris, M. P., Machemer, T., Maneval, D. C., and Gregory, R. J. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther., 2: 191-197, 1995.
12. Qian, C., Idoate, M., Bilbao, R., Sangro, B., Bruna, O., Vazquez, J., and Prieto, J. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum. Gene Ther., 8: 349-358, 1997.
13. Habib, N. A., Ding, S. F., el-Masry, R., Mitry, R. R., Honda, K., Michail, N. E., Dalla Serra, G., Izzi, G., Greco, L., Bassyouni, M., el-Toukhy, M., and Abdel-Gaffar, Y. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect. Prev., 20: 103-107, 1996.
14. Mitry, R. R., Sarraf, C. E., Wu, C. G., Pignatelli, M., and Habib, N. A. Wild-type p53 induces apoptosis in Hep3B through up-regulation of bax expression. Lab. Investig., 77: 369-378, 1997.
15. Puisieux, A., Ponchel, F., and Ozturk, M. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene, 8: 487-490, 1993.
16. Bui, L. A., Butterfield, L. H., Kim, J. Y., Ribas, A., Seu, P., Lau, R., Glaspy, J. A., McBride, W. H., and Economou, J. S. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum. Gene Ther., 8: 2173-2182, 1997.
17. Aldeghi, R., Lissoni, P., Barni, S., Ardizzoia, A., Tancini, G., Piperno, A., Pozzi, M., Ricci, G., Conti, A., and Maestroni, G. J. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur. J. Cancer, 30A: 167-170, 1994.
18. Huang, H., Chen, S. H., Kosai, K., Finegold, M. J., and Woo, S. L. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther., 3: 980-987, 1996.
19. Becker, F. F., Stillman, D., and Sell, S. Serum α-fetoprotein in a mouse strain (C3H-Avy fB) with spontaneous hepatocellular carcinomas. Cancer Res., 37: 870-872, 1977.
20. Kirkwood, J. M., Lotze, M. T., and Yasko, J. M. Current Career Therapeutics, p. 344. Philadelphia: Current Medicine, 1994.
21. Mizejewski, G., and Chao, E. Characterization of murine hepatoma BW7756. III. Hematological profile of a tumor-associated anemia. Int. J. Cancer, 35: 813-819, 1985.
22. Widen, S. G., and Papaconstantinou, J. Liver-specific expression of the mouse α-fetoprotein gene is mediated by cis-acting DNA elements. Proc. Natl. Acad. Sci. USA, 83: 8196-8200, 1986.
23. Zhang, D. E., Hoyt, P. R., and Papaconstantinou, J. Localization of DNA protein-binding sites in the proximal and distal promoter regions of the mouse α-fetoprotein gene. J. Biol. Chem., 265: 3382-3391, 1990.
24. Mizejewski, G. J. α-Fetoprotein signal sequences: a proposed mechanism for sub-cellular localization and organelle targeting. J. Theor. Biol., 176: 103-113, 1995.
25. Ruoslahti, E. α-Fetoprotein in cancer and fetal development. Adv. Cancer Res., 29: 275-346, 1979.
26. Chen, H., Egan, J. O., and Chiu, J. F. Regulation and activities of α-fetoprotein. Crit. Rev. Eukaryotic Gene Expr., 7: 11-41, 1997.
27. Sheppard, H. W., Jr., Sell, S., Trefts, P., and Bahu, R. Effects of α-fetoprotein on murine immune responses. I. Studies on mice J. Immunol., 119: 91-97, 1977.
28. Sell, S., Sheppard, H. W., Jr., and Poler, M. Effects of α-fetoprotein on murine immune responses. II. Studies on rats. J. Immunol., 119: 98-103, 1977.
29. Lu, C. Y., Changelian, P. S., and Unanue, E. R. α-Fetoprotein inhibits macrophage expression of Ia antigens. J. Immunol., 132: 1722-1727, 1984.
30. Kamata, Y. The prevention of chemical hepatocarcinogenesis in rats by combining active and passive immunization with α-fetoprotein. Tumour Biol., 6: 243-256, 1985.
31. Hirai, H., Tsukada, Y., Hara, A., Hibi, N., Nishi, S., Wepsic, H. T., Koji, T., and Ishii, N. Purification of specific antibody to α-fetoprotein and its immunological effect on cancer cells. J. Chromatogr., 215: 195-210, 1981.
32. Taga, H. The effect of active immunization of rats with heterologous α-fetoprotein upon hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene. Gann, 74: 248-257, 1983.
33. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
34. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., Renauld, J-P., and Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.
35. Brasseur, F., Marchand, M., Vanwijck, R., Herin, M., Lethe, B., Chomez, P., and Boon, T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int. J. Cancer, 52: 839-841, 1992.
36. Coulie, P. G., Weynants, P., Lehmann, F., Herman, J., Brichard, V., Wolfel, T., Van Pel, A., De Plaen, E., Brasseur, F., and Boon, T. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J. Immunother., 14: 104-109, 1993.
37. Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
38. Corny, R. M., LoBuglio, A. F., Kantor, J., Schlom, J., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., Abrams, S., and Curiel, D. T. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res., 54: 1164-1168, 1994.
39. Kaufman, H., Schlom, J., and Kantor, J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer, 48: 900-907, 1991.
40. Robbins, P. F., Kantor, J. A., Salgaller, M., Hand, P. H., Fernsten, P. D., and Schlom, J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res., 51: 3657-3662, 1991.
41. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
42. Butterfield, L. H., Jilani, S. M., Chakraborty, N. G., Bui, L. A., Ribas, A., Dissette, V. B., Lau, R., Gamradt, S. C., Glaspy, J. A., McBride, W. H., Mukherji, B., and Economou, J. S. Generation of melanoma-specific cyloloxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol., 161: 5607-5613, 1998.
43. Ribas, A., Butterfield, L. H., McBride, W. H., Dissette, V. B., Koh, A., Vollmer, C. M., Hu, B., Chen, A. Y., Glaspy, J. A., and Economou, J. S. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther., 6: in press, 1999.
44. Ribas, A., Butterfield, L. H., McBride, W. H., Jilani, S. M., Bui, L. A., Vollmer, C. M., Lau, R., Dissette, V. B., Hu, B., Chen, A. Y., Glaspy, J. A., and Economou, J. S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 57: 2865-2869, 1997.
45. Butterfield, L. H., Stoll, T. C., Lau, R., and Economou, J. S. Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. Gene (Amst.), 191: 129-134, 1997.
46. Toloza, E. M., Hunt, K., Swisher, S., McBride, W., Lau, R., Pang, S., Rhoades, K., Drake, T., Belldegrun, A., Glaspy, J., and Economou, J. S. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther., 3: 11-17, 1996.
47. Stuber, G., Leder, G. H., Storkus, W. T., Lotze, M. T., Modrow, S., Szekely, L., Wolf, H., Klein, E., Karre, K., and Klein, G. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur. J. Immunol., 24: 765-768, 1994.
48. Nijman, H. W., Houbiers, J. G., Vierboom, M. P., van der Burg, S. H., Drijfhout, J. W., D'Amaro, J., Kenemans, P., Melief, C. J., and Kast, W. M. Identification of peptide sequences that potentially trigger HLA-A2.1 -restricted cytotoxic T lymphocytes. Eur. J. Immunol., 23: 1215-1219, 1993.
49. Storkus, W. J., Zeh, H. J. d., Salter, R. D., and Lotze, M. T. Identification of T-cell epitopes: rapid isolation of class 1-presented peptides from viable cells by mild acid elution. J. Immunother., 14: 94-103, 1993.
50. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., and Melief, C. J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol., 156: 3308-3314, 1996.
51. Arthur, J. F., Butterfield, L. H., Roth, M. D., Bui, L. A., Kiertscher, S. M., Lau, R., Dubinett, S., Glaspy, J., McBride, W. H., and Economou, J. S. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther., 4: 17-25, 1997.
52. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
53. Mayer, S., Scheibenbogen, C., Lee, K. H., Keilholz, W., Stevanovic, S., Rammensee, H. G., and Keilholz, U. A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J. Immunol. Methods, 197: 131-137, 1996.
54. + T lymphocytes secreting tumor necrosis factor or in response to HLA-A2.1 -binding melanoma and viral peptide antigens. J. Immunol. Methods, 191: 131-142, 1996.
55. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176: 1693-1702, 1992.
56. Celis, E., Fikes, J., Wentworth, P., Sidney, J., Southwood, S., Maewal, A., Del Guercio, M. F., Sette, A., and Livingston, B. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol. Immunol., 31: 1423-1430, 1994.
57. Falk, K., and Rotzschke, O. Consensus motifs and peptide ligands of MHC class I molecules. Semin. Immunol., 5: 81-94, 1993.
58. Rammensee, H. G., Fait, K., and Rotzschke, O. MHC molecules as peptide receptors. Curr. Opin. Immunol., 5: 35-44, 1993.
59. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell, 74: 929-937, 1993.
60. Reeves, M. E., Royal, R. E., Lam, J. S., Rosenberg, S. A., and Hwu, P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res., 56: 5672-5677, 1996.
61. Zhai, Y., Yang, J. C., Kawakami, Y., Spiess, P., Wadsworth, S. C., Cardoza, L. M., Couture, L. A., Smith, A. E., and Rosenberg, S. A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol., 156: 700-710, 1996.
62. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell, 74: 929-937, 1999.
63. Kubo, R. T., Sette, A., Grey, H. M., Appella, E., Sakaguchi, K., Zhu, N. Z., Arnott, D., Sherman, N., Shabanowitz, J., Michel, H., Bodnar, W. M., Davis, T. A., and Hunt, D. F. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol., 152: 3913-3924, 1994.
64. Chen, Y., Sidney, J., Southwood, S., Cox, A. L., Sakaguchi, K., Henderson, R. A., Appella, E., Hunt, D. F., Sette, A., and Engelhard, V. H. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol., 152: 2874-2881, 1994.
65. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., and Rammensee, H. G. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur. J. Immunol., 22: 2453-2456, 1992.
66. Fruci, D., Rovero, P., Falasca, G., Chersi, A., Sorrentino, R., Butler, R., Tanigaki, N., and Tosi, R. Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I a chains. Hum. Immunol., 38: 187-192, 1993.
67. van der Burg, S. H., Visseren, M. J., Offringa, R., and Melief, C. J. Do epitopes derived from autoantigens display low affinity for MHC class I? Immunol. Today, 18: 97-98, 1997.
68. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
69. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
70. Kang, X., Kawakami, Y., el-Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J. R., Appella, E., Rosenberg, S. A., and Robbins, P. F. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol., 155: 1343-1348, 1995.
71. Skipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V., Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Jr., Boon, T., Hunt, D. F., and Engelhard, V. H. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med., 183: 527-534, 1996.
72. Tsomides, T. J., Reilly, E. B., and Eisen, H. N. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self sequences: autoimmune nature of the anti-melanoma CTL response. Int. Immunol., 9: 327-338, 1997.
73. Wang, R. F., Johnston, S. L., Southwood, S., Sette, A., and Rosenberg, S. A. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol., 160: 890-897, 1998.
74. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chesnut, R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med., 173: 1007-1015, 1991.
75. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.